30
Participants
Start Date
May 8, 2023
Primary Completion Date
June 30, 2024
Study Completion Date
June 30, 2028
Tislelizumab
The participants will receive 3 cycles of Tislelizumab, with 21 days each. 200mg of Tislelizumab will be used intravenously on the first day of each cycle.
Albumin paclitaxel
The participants will receive 3 cycles of Albumin paclitaxel, with 21 days each. 200mg/m\^2 of Albumin paclitaxel will be used intravenously on the first day of each cycle.
Cisplatin
The participants will receive 3 cycles of Cisplatin, with 21 days each. 20mg/m\^2 of Cisplatin will be used intravenously on days 1 through 3 of each cycle.
5-Fluorouracil
The participants will receive 3 cycles of 5-Fluorouracil, with 21 days each. 600mg/m\^2/d of 5-Fluorouracil will be used as a 120-hour continuous intravenous infusion on days 1 through 5.
RECRUITING
First affiliated hospital, School of Medicine, Zhejiang University, Hangzhou
Weijia Fang, MD
OTHER